INTRODUCTION
for colorectal carcinoma from January 2012 to March 2017 at Ortadogu Private Hospital, Adana, Turkey. Cukurova University Clinical Ethical Board approved this study.
Inclusion criteria were patients who underwent surgery with stage 3 and stage 4 colorectal cancer. The exclusion criteria were patients who had recurrent colorectal cancer and/or accompanying cancer in another region. No chemotherapy or radiotherapy was given before operation. Clinicopathological findings such as gender, age, tumor size, tumor site, histological stage, and grade were recorded through hospital database and contact with physician, if necessary. The tumors were classified by stages with respect to the 7 th volume of the AJCC/UICC TNM classification. 9 In all cases, all existing sections stained with hematoxylin and eosin were analysed. Four micrometer thick sections of the formalin-fixed and paraffin-embedded tissues were put down in poly-L-lysine-coated slides for immunohistochemistry. 5 Immunohistochemical staining was performed with streptoavidin-biotin method. Briefly, the sections were de-paraffinised and incubated with 3% hydrogen peroxide for twenty minutes to block endogenous peroxidase activity. Prior to immunostaining, antigen retrieval was applied. Subsequently, slides were incubated with CDX2 (clone DAK-CDX2, dako) and Villin (clone 1D2 C3, dako) at room temperature with primary antibodies for 60 minutes. Standard avidin-biotinperoxidase complex (ABC) method was applied by employing LabVision Secondary Detection Kit (UltraVision Detection System Anti-polyvalent, HRP). AEC was applied as chromogen. Finally, the samples were sited on PBS having diaminobenzidine and 1% hydrogen peroxide for five minutes and counterstained with hematoxylin solution for one minute and mounted.
A tumor was recorded positive, if greater than 5% of the tumor cells exhibited nuclear staining for CDX2 and apical membranous and/or cytoplasmic staining for Villin. 5 The percentage of positive cells was scored in a semiquantitative method according to the following scheme: 0 (less than 5% of tumor cells); 1+ (positive signal of any intensity in 5-25% of tumor cells); 2+ (26-50% of tumor cells); 3+ (51-75% of tumor cells); and 4+ (greater than 75% of tumor cells, Figure 1 ).
Statistical analysis was performed using the statistical package SPSS software (Version 22.0, SPSS Inc., Chicago, IL, USA). If continuous variables were normal, they were describle as the mean ±standard deviation they were described as the median. The catagorical variables between the groups were analysed by using the Chi-square test or Fisher Exc. test. Overall survival time was defined as the years elapsed between date of after operation and death as a result of disease (or the last follow-up date). Overall survival was analysed using the Wald test, and the log-rank test was used to examine their relationship when different parameters were applied. The survival curve was plotted using the standard Kaplan-Meier methodology.
Values of p<0.05 were considered statistically significant.
RESULTS
The general characteristics and the distribution of the clinicopathologic data of the patients are shown in Table I . Fourty-one (58. 6%) were men and 29 (41. 4%) were women; and median age was 62 (29-84) years. There were 19 (27.1%) patients of right colon carcinoma, 17 (24.3%) patients of left colon carcinoma, and 34 (48.6%) cases of rectal cancer. The mean size of the tumor was 6.0 ±2.0 cm ranging from 3.0 to 12.0 cm.
The pathologic tumor classification found well differentiated adenocarcinoma in 13 patients (18.6%), moderately differentiated adenocarcinoma in 53 cases (75.7%), and poorly differentiated adenocarcinoma in four cases (5.7%).
The pathological surgical specimen nodal classification was N0 in 34 cases (48.6%), N1 in 23 cases (32.9%), and N2 in 13 cases (18.6%). Most patients belonged to stage 3 (n=66, 94.3%). Four patients (n=4, 5.7%) had distant metastasis. Twelve (17.1 %) patients died at the endpoint of the study. Positive expression of CDX2 and Villin was 65.7% (46 out of 70), 71.4% (50 out of 70), respectively.
The distribution of Villin expression in colon carcinoma samples in relation to clinicopathological characteristics is shown in Table II . There was no statically important distinction with any of the clinicopathological parameters like age, location, depth of invasion, lymph node metastasis, grade, TNM stage and lymphovascular and perineural invasion. Kaplan-Meier survival analyses did not show a significant association with villin immunoexpression and survival ( Figure 2 ).
The distribution of CDX2 expression in relation to clinicopathological characteristics is shown in Table III . Similarly, Villin there was no important relation between CDX2 expression and clinicopathological parameters. The Kaplan-Meier survival analyses did not show a significant association between CDX2 immunoexpression and survival (Figure 3 ).
DISCUSSION
Because of the heterogeneity of the disease outcome, it is much more important to understand the molecular pathology underlying CRC to discover more prognostic molecules and finally to improve therapeutic interventions. It has been suggested that it controls numerous genes that are involved in multiple procedures such as proliferation, migration, cell adhesion and tumorigenesis. 10 It is used as a prognostic factor in gastric cancer; but its prognostic significance in colorectal cancer remains contro-versial. 11, 12 Preceding researches have conducted a broad difference in the ratio of CRCs that express CDX2. 13, 14 Kaimaktchiev et al. determined CDX2 expression in 86% of CRC and he found an inverse correlation with stage and grade. 9 In a meta-analysis of 9 studies, Yu et al.
showed that low expression of CDX2 was relevant to a poor outcome in colorectal cancer. 2 Baba et al. 15 had found that CDX2 loss was independently related with female gender, high tumor grade, and advanced tumor. In their study, CDX2 loss was independently related with poor outcome among patients with a family history of colorectal carcinoma. However, it was not in those with no family history. Matsuda et al. conducted CDX2 expression in 80% of CRC and he found an inverse correlation with survival. 16 Lugli et al. found that loss of CDX2 expression associated with MMR deficiency, 14 but not outcome. Zheng et al. found CDX2 expression in 80% of CRC, and he showed that CDX2 inversely related with grade and stage. 17 Bauer et al. showed that CDX2 expression conversely related to poor prognosis in right-sided cancers. 18 CDX2 was found to be expressed in 65.7% of cases.
There was no statistically important correlation between CDX2 expression and patients' age, tumour location, depth of invasion, grade, metastasis of lymph node, lymphovascular and perineural invasion. Survival analysis also did not show a significant association with immunoexpression of CDX2.
In the presently studied tumour samples, Villin was found to be expressed in 71.4% of cases. However, like CDX2 there was no statistically important correlation between Villin expression and patients' age, tumour location, depth of invasion, grade, metastasis of lymph node, lymphovascular and perineural invasion. Survival analysis did not show a significant relation with immunoexpression of Villin. Similarly, Arango et al. found no such association between Villin staining intensity and overall prognosis in CRC. 19 However, in a study by Al-Maghrabi et al., Villin immunoexpression in CRC was related with better survival, well-differentiated cancers, and small-sized cancers. 8 The most important finding in this study is the close correlation of CDX2 and Villin (r=0.76, p=0.0001). Literature could not be found about any study about the correlation of these molecules in CRC. Yamamichi et al. conducted a relation between expression of the highly correlated CDX2 transcription factor and Villin expression in a study of gastric cancer. 20 They concluded that CDX2 regulates the expression of intestinal villus by collecting the Brm-type SWI / SNF complex into the Villin promoter. 20 CONCLUSION CDX2 and Villin were not associated with any of the clinicopathologic parameters like age, sex, location, grade, metastasis of lymph node, lymphovascular and perineural invasion. Survival analysis also did not show a significant association with immunoexpression of these molecules. Our findings proposed that CDX2 and Villin might not be useful as a prognostic factor in advanced stage colorectal carcinoma. More in vivo and in vitro researches are needed for further clarification of how these two molecules might have a relation in tumorigenesis of CRC. 
